RE: on wards and up19 Mar 2017 15:40
There is one small area of concern and that is that 2016 half on half sales for Europe and the USA did not seem to grow as fast as elsewhere. Some evidence that this this is just an outlier would reassure.
I am not so much interested in the results ( although if pre-tax profit beats consensus forecasts of around 34-36 million, attributable eps of 25p-26p that would be a big plus); what we need is optimistic guidance on;
1 Accelerating growth at the beginning of 2017
2 Success of new products
3 Evidence of volume growth in non-UK markets
4 PEG remaining well below 1 ( which it should on consensus expectations)
If, unfortunately, results counter in any way the trading update ( sales below 102 million, rate of growth pull back etc) than undoubtedly the share price will retreat 10% -20%.
Fevertree has a history of beating expectations, as a previous poster pointed out, so I remain optimistic , but a little apprehensive all the same